

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US),
LLC,
Petitioner,

v.

CIPLA LTD,
Patent Owner.

Case IPR2020-00368
Patent 8,163,723

**PATENT OWNER MANDATORY NOTICE INFORMATION
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8(a)(3), Patent Owner, Cipla Ltd. (“Cipla”), hereby files its Mandatory Notices:

A. Real Party-in-Interest (§ 42.8(b)(1))

The following real parties-in-interest are identified: Cipla Ltd, Meda Pharmaceuticals Inc., Meda AB, Mylan N.V., Mylan Inc., and Mylan Pharmaceuticals Inc.

B. Related Matters (§ 42.8(b)(2))

(1) The following matters involve U.S. Patent No. 8,163,723 (“the ’723 Patent), related U.S. Patent No. 8,168,620 (“the ’620 Patent”), and related U.S. Patent No. 9,259,428 (“the ’428 Patent”):

- *Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.*, No. 1:15-cv00785-LPS (D. Del.) (dismissed on July 28, 2017);
- *Meda Pharmaceuticals Inc. v. Perrigo UK FINCO Ltd.*, No. 1:16-cv-00794-LPS (D. Del.) (dismissed on July 7, 2017); and
- *Meda Pharmaceuticals, Inc. v. Apotex Inc.*, No. 1:14-cv-01453-LPS (D. Del.) (dismissed on May 17, 2017).

(2) The following matters involved the related ’620 Patent:

- *Argentum Pharmaceuticals LLC v. Cipla Ltd.*, IPR2017-00807 (PTAB) (terminated by joint motion on May 21, 2018).

(3) The following matters involve co-pending petitions for *inter partes*

review:

- *GlaxoSmithKline Consumer Healthcare Holdings (US) v. Cipla Ltd.*, IPR2020-00369 (pending) (the '620 patent),
- *GlaxoSmithKline Consumer Healthcare Holdings (US) v. Cipla Ltd.*, IPR2020-00370 (pending) (the '428 patent), and
- *GlaxoSmithKline Consumer Healthcare Holdings (US) v. Cipla Ltd.*, IPR2020-00371 (pending) (U.S. Patent No. 9,901,585).

C. Counsel and Service Information (§§ 42.8(b)(3) and (4))

Patent Owner identifies its lead and backup counsel as shown below:

Lead Counsel	First Backup Counsel
Brandon M. White (Reg. No. 52,354) Perkins Coie LLP 700 13th St., NW, Suite 600 Washington, DC 20005 White-ptab@perkinscoie.com Tel: (202) 654-6206 Fax: (202) 654-9681	Emily J. Greb (Reg. No. 68,244) Perkins Coie LLP 33 East Main Street, Suite 201 Madison, WI 53703 Greb-ptab@perkinscoie.com Tel: (608) 663-7494 Fax: (608) 283-4494
Backup Counsel	
Nathan K. Kelley (Reg. No. 45,295) Perkins Coie LLP 700 13th St., NW, Suite 600 Washington, DC 20005 Kelley_nathan-ptab@perkinscoie.com Tel: (202) 654-3343 Fax: (202) 654-9574	

Please address all correspondence to the lead and backup counsel at the above

addresses and to dymista@perkinscoie.com. Patent Owner consents to electronic service to the e-mail addresses above for lead and backup counsel and to dymista@perkinscoie.com.

D. Patent Owner Preliminary Response

Patent Owner reserves the right to file a preliminary response at a separate date.

E. Patent Owner Power of Attorney

A Power of Attorney to transact all business in the United States Patent and Trademark office in connection with above-referenced *Inter Partes* Review from Patent Owner Cipla Ltd. to the above-designated counsel at Perkins Coie LLP is being filed concurrently with these Mandatory Notices.

Date: February 21, 2020

Respectfully submitted,

/s/ Brandon M. White

Brandon M. White

Reg. No. 52,354

Counsel for Cipla Ltd.

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6, I hereby certify that the foregoing Patent Owner Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on February 21, 2020, by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Charles E. Lipsey, charles.lipsey@finnegan.com,

Trenton A. Ward, trenton.ward@finnegan.com,

Richard B. Racine, rich.racine@finnegan.com,

Joann M. Neth, Ph.D., joann.neth@finnegan.com,

Shana K. Cyr, Ph.D., shana.cyr@finnegan.com, and

Cipla-GSK-IPR@finnegan.com.

Date: February 21, 2020

Respectfully submitted,

/s/ Brandon M. White

Brandon M. White

Reg. No. 52,354

Counsel for Cipla Ltd.